These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

674 related articles for article (PubMed ID: 32763818)

  • 1. Existing highly accumulating lysosomotropic drugs with potential for repurposing to target COVID-19.
    Norinder U; Tuck A; Norgren K; Munic Kos V
    Biomed Pharmacother; 2020 Oct; 130():110582. PubMed ID: 32763818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The lysosome: A potential juncture between SARS-CoV-2 infectivity and Niemann-Pick disease type C, with therapeutic implications.
    Ballout RA; Sviridov D; Bukrinsky MI; Remaley AT
    FASEB J; 2020 Jun; 34(6):7253-7264. PubMed ID: 32367579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COVID-19, Chloroquine Repurposing, and Cardiac Safety Concern: Chirality Might Help.
    Lentini G; Cavalluzzi MM; Habtemariam S
    Molecules; 2020 Apr; 25(8):. PubMed ID: 32316270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection.
    Juurlink DN
    CMAJ; 2020 Apr; 192(17):E450-E453. PubMed ID: 32269021
    [No Abstract]   [Full Text] [Related]  

  • 5. Widely available lysosome targeting agents should be considered as potential therapy for COVID-19.
    Homolak J; Kodvanj I
    Int J Antimicrob Agents; 2020 Aug; 56(2):106044. PubMed ID: 32522674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drugs, Metabolites, and Lung Accumulating Small Lysosomotropic Molecules: Multiple Targeting Impedes SARS-CoV-2 Infection and Progress to COVID-19.
    Blaess M; Kaiser L; Sommerfeld O; Csuk R; Deigner HP
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety considerations for chloroquine and hydroxychloroquine in the treatment of COVID-19.
    Gevers S; Kwa MSG; Wijnans E; van Nieuwkoop C
    Clin Microbiol Infect; 2020 Sep; 26(9):1276-1277. PubMed ID: 32422406
    [No Abstract]   [Full Text] [Related]  

  • 8. The Anatomy of the SARS-CoV-2 Biomedical Literature: Introducing the CovidX Network Algorithm for Drug Repurposing Recommendation.
    Gates LE; Hamed AA
    J Med Internet Res; 2020 Aug; 22(8):e21169. PubMed ID: 32735546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insights from nanomedicine into chloroquine efficacy against COVID-19.
    Hu TY; Frieman M; Wolfram J
    Nat Nanotechnol; 2020 Apr; 15(4):247-249. PubMed ID: 32203437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Excessive lysosomal ion-trapping of hydroxychloroquine and azithromycin.
    Derendorf H
    Int J Antimicrob Agents; 2020 Jun; 55(6):106007. PubMed ID: 32389720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chloroquine and hydroxychloroquine in the treatment of malaria and repurposing in treating COVID-19.
    Lei ZN; Wu ZX; Dong S; Yang DH; Zhang L; Ke Z; Zou C; Chen ZS
    Pharmacol Ther; 2020 Dec; 216():107672. PubMed ID: 32910933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: A narrative review.
    Hashem AM; Alghamdi BS; Algaissi AA; Alshehri FS; Bukhari A; Alfaleh MA; Memish ZA
    Travel Med Infect Dis; 2020; 35():101735. PubMed ID: 32387694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review on possible modes of action of chloroquine/hydroxychloroquine: repurposing against SAR-CoV-2 (COVID-19) pandemic.
    Tripathy S; Dassarma B; Roy S; Chabalala H; Matsabisa MG
    Int J Antimicrob Agents; 2020 Aug; 56(2):106028. PubMed ID: 32450198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COVID-19/SARS-CoV-2 Infection: Lysosomes and Lysosomotropism Implicate New Treatment Strategies and Personal Risks.
    Blaess M; Kaiser L; Sauer M; Csuk R; Deigner HP
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32668803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic review on use of aminoquinolines for the therapeutic management of COVID-19: Efficacy, safety and clinical trials.
    Patil VM; Singhal S; Masand N
    Life Sci; 2020 Aug; 254():117775. PubMed ID: 32418894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19.
    Meo SA; Klonoff DC; Akram J
    Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4539-4547. PubMed ID: 32373993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chloroquine and hydroxychloroquine in covid-19.
    Ferner RE; Aronson JK
    BMJ; 2020 Apr; 369():m1432. PubMed ID: 32269046
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical evidence for repurposing chloroquine and hydroxychloroquine as antiviral agents: a systematic review.
    Rodrigo C; Fernando SD; Rajapakse S
    Clin Microbiol Infect; 2020 Aug; 26(8):979-987. PubMed ID: 32470568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repurposing antimalarials and other drugs for COVID-19.
    Schlagenhauf P; Grobusch MP; Maier JD; Gautret P
    Travel Med Infect Dis; 2020; 34():101658. PubMed ID: 32247925
    [No Abstract]   [Full Text] [Related]  

  • 20. COVID-19 Pandemic - A Narrative Review of the Potential Roles of Chloroquine and Hydroxychloroquine.
    de Barros CM; Almeida CAF; Pereira B; Costa KCM; Pinheiro FA; Maia LDB; Trindade CM; Garcia RCT; Torres LH; Diwan S; Boralli VB
    Pain Physician; 2020 Aug; 23(4S):S351-S366. PubMed ID: 32942793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.